drugset / Trial / NCT00275132
Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 3
Completed
670 enrolled
University College, London
Cancer Research UK · collabRoche Pharma AG · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether erlotinib is more effective than a placebo in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works compared to a placebo in treating patients with stage III or stage IV non-small cell lung cancer.
Timeline
- Start
- 2005-04
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |